SALMONELLA

VolverVolver

Resultados 67 resultados LastUpdate Última actualización 22/05/2022 [12:16:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 90 días / Applications published in the last 90 days



Página1 de 3 nextPage   por página


Application of Acetylacetone in Inhibiting Growth of Cyanobacteria

NºPublicación: US2022151228A1 19/05/2022

Solicitante:

UNIV NANJING [CN]

WO_2021139168_A1

Resumen de: US2022151228A1

Disclosed is application of acetylacetone in inhibiting the growth of cyanobacteria, that is, acetylacetone is added in water disturbed with cyanobacteria, and the dosage of acetylacetone is not less than 7 mg/L to inhibit the growth of cyanobacteria. Acetylacetone inhibits the growth of cyanobacteria by inhibiting photosynthesis, has a better algicidal effect than common algaecides, is harmless to common bacteria such as Escherichia coli, Salmonella, Bacillus subtilis, and Staphylococcus aureus, and is environmentally friendly and easy to popularize and apply.

traducir

Live Attenuated Non-Transmissible Vaccines

NºPublicación: US2022154135A1 19/05/2022

Solicitante:

UNIV MARYLAND [US]

WO_2020237246_A1

Resumen de: US2022154135A1

The present invention provides genetically modified microorganisms with reduced transmissibility, wherein the microorganism has been genetically modified to express a single stranded binding protein (SSB) regulated by an arabinose responsive promoter, wherein the microorganism has a reduced growth capacity in the absence of arabinose.

traducir

SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES, SHIGA TOXIN EFFECTOR SCAFFOLDS, AND CELL-TARGETING MOLECULES FOR SITE-SPECIFIC CONJUGATION

NºPublicación: US2022152213A1 19/05/2022

Solicitante:

MOLECULAR TEMPLATES INC [US]

US_2021008208_A1

Resumen de: US2022152213A1

The present invention provides Shiga toxin A Subunit derived polypeptides, scaffolds, and cell-targeting molecules comprising amino acid substitutions which equip the molecules with site-specific positions (and often unique amino acid residues in the molecule) for linking other molecules while retaining Shiga toxin function(s), such as, e.g., efficient intracellular routing and/or potent cytotoxicity. The present invention also provides cell-targeting molecules, and/or components thereof, which comprise site-specific positions for linking other molecules, such as, e.g., agents that alters a property of the cell-targeting molecule or a cargo for delivery. Certain molecules comprising a polypeptide of the present invention exhibit reduced immunogenicity and/or are well-tolerated by mammals. The cell-targeting molecules of the present invention, and compositions thereof, have uses, e.g., for the selective delivery of cargos to target-expressing cells and as diagnostic and/or therapeutic molecules for the treatment of a variety of diseases, disorders, and conditions, which include genetic disorders, genetic predispositions, infections, cancers, tumors, growth abnormalities, and/or immune disorders.

traducir

METHODS OF INCREASING VACCINE EFFICACY

NºPublicación: CN114502573A 13/05/2022

Solicitante:

基因组保护股份有限公司

CA_3149593_PA

Resumen de: WO2021041822A1

The present invention relates, in part, to compositions and methods for enhancement of an immune response and for increased vaccine efficacy by stimulation of the TLR5 receptor, for example, with a recombinant TLR5 agonist (e.g., a flagellin-based agent or variant thereof).

traducir

ANTIMICROBIAL AGENT USEFUL FOR WIDE RANGE OF MICROORGANISMS INCLUDING CORONAVIRUS (FOR EXAMPLE, SARS-CoV-2)

NºPublicación: WO2022097729A1 12/05/2022

Solicitante:

IPPAN ZH SHINIRYOZAIDAN [JP]

Resumen de: WO2022097729A1

The present disclosure provides a novel antimicrobial agent useful for a wide range of microorganisms including coronavirus (for example, SARS-CoV-2). Provided is an antimicrobial agent against microorganisms, the antimicrobial agent comprising metal ions, L-cysteine, L-ascorbic acid, and a surfactant, wherein the microorganisms include coronavirus. The coronavirus may be SARS-CoV-2. An antimicrobial agent according to the present invention may also be effective against influenza virus, adenovirus, norovirus, Escherichia coli, Pseudomonas aeruginosa, Salmonella, Staphylococcus aureus, Vibrio parahaemolyticus, Campylobacter, and Candida.

traducir

"AUTOLYTIC" SALMONELLA STRAIN, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN TUMOR TREATMENT

NºPublicación: WO2022094865A1 12/05/2022

Solicitante:

SHENZHEN INST OF ADV TECH CAS [CN]

Resumen de: WO2022094865A1

Provided are a genetically engineered bacterium and a preparation method therefor. The genetically engineered bacterium is a salmonella strain that has knocked out dapA or dapE gene. Also provided is an application of the strain in tumor treatment.

traducir

METHOD FOR CONSTRUCTING STRICTLY ANAEROBIC SALMONELLA, CONSTRUCTED STRICTLY ANAEROBIC SALMONELLA AND APPLICATION THEREOF

NºPublicación: WO2022094864A1 12/05/2022

Solicitante:

SHENZHEN INST OF ADV TECH CAS [CN]

Resumen de: WO2022094864A1

Provided are a method for constructing strictly anaerobic salmonella, the strictly anaerobic salmonella constructed using the method, and an application thereof in tumor treatment.

traducir

SALMONELLA STRAIN FOR PREVENTION AND TREATMENT OF CANCER AND USE THEREOF

NºPublicación: WO2022098213A1 12/05/2022

Solicitante:

UNIV NAT CHONNAM IND FOUND [KR]

Resumen de: WO2022098213A1

The present invention relates to a DNA construct and a strain into which a recombinant vector comprising the DNA construct is introduced. The DNA construct according to the present invention expresses an antioncogene operably linked downstream of first and second promoters in a host strain or cell, and thus has cancer prevention and treatment effects. In addition, the DNA construct of the present invention enables an antioncogene to be expressed at an appropriate dose for cancer treatment, by controlling doxycycline treatment.

traducir

CONSTRUCTION FOR PP2 OBLIGATE ANAEROBIC SALMONELLA STRAIN AND APPLICATION OF SAME IN TUMOR TREATMENT

NºPublicación: WO2022094867A1 12/05/2022

Solicitante:

SHENZHEN INST ADV TECH [CN]

Resumen de: WO2022094867A1

Provided are a PP2 gene sequence of an anaerobic activation promoter, an anaerobic gene loop regulated by a PP2 promoter, obligate anaerobic Salmonella typhimurium containing the anaerobic gene loop regulated by the PP2 promoter, a vector, and an application of the obligate anaerobic Salmonella typhimurium in tumor treatment. Also provided are a method for changing facultative anaerobic bacteria into obligate anaerobic bacteria, a method for treating cancers using anaerobic loop-regulated bacteria, and an application of the methods in tumor treatment.

traducir

SYSTEM, METHOD AND INTERFACE FOR PARALLEL PROCESSING OF ANTIMICROBIAL SUSCEPTIBILITY TESTS USING DIFFERENT SAMPLES

NºPublicación: US2022145352A1 12/05/2022

Solicitante:

SELUX DIAGNOSTICS INC [US]

JP_2021519091_A

Resumen de: US2022145352A1

An improved system, method and interface for automated rapid antimicrobial susceptibility testing (AST) is disclosed which includes, in one aspect, a carrier population station comprising a workstation having a graphic user interface (GUI). The GUI accepts information from a lab technologist, including information related to a scope of testing to be performed on a microorganism containing sample. The GUI controls intelligent assignment of microorganism containing samples to test panels in a manner that maximize utilization of the test carrier by grouping together samples of similar tests scopes and advantageously testing those samples using one multiplexed test panel. Customizing workflow in accordance with test scope to facilitate parallel processing of multiple samples advantageously reduces laboratory waste, decreases test latencies, increases AST system throughput and efficiency, and thus lowers the costs to the AST lab.

traducir

METHOD FOR LATERAL FLOW IMMUNOASSAY

NºPublicación: US2022146522A1 12/05/2022

Solicitante:

PURDUE RESEARCH FOUNDATION [US]

US_2020116729_PA

Resumen de: US2022146522A1

The present disclosure relates to a novel method for lateral flow immunoassay (LFIA) by utilizing plasmonic enhancement strategy. More specifically, the present disclosure provides a plasmonic enhanced lateral flow sensor (pLFS) concept by introducing a liposome-based amplification of the colorimetric signals on the lateral flow platform for ultrasensitive detection of pathogens.

traducir

TUMOR-DELIVERED MULTI-TARGET THERAPEUTICS FOR COLON CANCER

NºPublicación: US2022143105A1 12/05/2022

Solicitante:

UNIV ARIZONA STATE [US]

WO_2020172463_A1

Resumen de: US2022143105A1

The present disclosure relates to genetically modified strains of Salmonella, engineered to be tumor navigating, self-eradicating, and armed with decoy polypeptides that bind endogenous ligand and block activation of signal transduction cascades associated with cancer cell proliferation and tumor growth. Also provided herein are methods of producing and methods of using such genetically modified Salmonella strains to treat cancer.

traducir

Inert carrier indirect agglutination test detection system and application thereof

NºPublicación: GB2600848A 11/05/2022

Solicitante:

UNIV YANGZHOU [CN]

WO_2021227514_A1

Resumen de: GB2600848A

Provided are an inert carrier indirect agglutination test detection system and an application thereof. Specifically, the indirect agglutination test detection system comprises an inert carrier bacteria S9 and a complex S9-P that expresses and carries a P antigen factor on the surface thereof. The inert carrier indirect agglutination test detection system only carries the P antigen factor, and has a positive particle agglutination reaction that is visible to the naked eye with the whole blood or serum of Salmonella pullorum and Salmonella gallinarum-infected chickens at certain concentration conditions, and has no non-specific cross-agglutination reactions with the serum or whole blood of different background chicken sources without Salmonella pullorum and Salmonella gallinarum infections. S9-P is based on a glass plate agglutination reaction operation platform. Agglutination reaction particles are visible to the naked eye, and the result is clear and easy to determine. The test and result determinations are complete within two minutes. S9-P is suitable for the targeted and specific detection of Salmonella pullorum and Salmonella gallinarum in chicken flocks, and has good application prospects in the field monitoring and diagnosis of chicken flocks.

traducir

IMMUNOSTIMULATORY BACTERIA ENGINEERED TO COLONIZE TUMORS, TUMOR-RESIDENT IMMUNE CELLS, AND THE TUMOR MICROENVIRONMENT

NºPublicación: US2022135980A1 05/05/2022

Solicitante:

ACTYM THERAPEUTICS INC [US]

JP_2022524951_A

Resumen de: US2022135980A1

Provided are delivery immunostimulatory bacteria that have enhanced colonization of tumors, the tumor microenvironment and/or tumor-resident immune cells, and enhanced anti-tumor activity. The immunostimulatory bacteria are modified by deletion of genes encoding the flagella or by modification of the genes so that functional flagella are not produced, and/or are modified by deletion of pagP or modification of pagP to produce inactive PagP product. As a result, the immunostimulatory bacteria are flagellin− and/or pagP−. The immunostimulatory bacteria optionally have additional genomic modifications so that the bacteria are adenosine and/or purine auxotrophs. The bacteria optionally are one or more of asd−, purI− and msbB−. The immunostimulatory bacteria, such as Salmonella species, are modified to encode proteins that induce type I interferon (IFN) expression, or that are variants thereof that have increased activity to induce type I IFN expression, or that are variants thereof that result in constitutive expression of type I IFN. The bacteria can encode a modified Stimulator of Interferon Genes (STING) protein from a non-human species, that has lower NF-κB signaling activity, and, optionally, higher type I IFN pathway signaling activity, compared to human STING. The bacteria preferentially infect immune cells in the tumor microenvironment, or tumor-resident immune cells, and/or induce less cell death in immune cells than in other cells. Also provided are methods of

traducir

DIRECT DELIVERY OF VITAMINS TO INHIBIT MICROBIAL PATHOGENS

NºPublicación: WO2022090254A1 05/05/2022

Solicitante:

DSM IP ASSETS BV [NL]

Resumen de: WO2022090254A1

This invention relates to the direct delivery of a vitamin composition to the large intestine, in order to decrease the growth of pathogenic organisms in the gut, such as Adherent Invasive E. coli (AIEC), Salmonella enteriditis and Clostridium difficile. The vitamin composition comprises a combination of the following vitamins: Vitamin C, Vitamin B2, Vitamin B3, Vitamin B5, Vitamin B6 and folic acid.

traducir

SARS-COV-2 VACCINE ANTIGEN PRESENTING SYSTEM OF NTD DOMAIN PROTEIN SECRETED AND EXPRESSED BY ATTENUATED SALMONELLA TYPHIMURIUM, AND USE THEREOF

NºPublicación: WO2022087854A1 05/05/2022

Solicitante:

NANJING JIRUIKANG BIOTECHNOLOGY RES INSTITUTE CO LTD [CN]
CHANGZHOU NANJING UNIV INSTITUTE OF HIGH TECHNOLOGY [CN]

CN_114480462_A

Resumen de: WO2022087854A1

A SARS-CoV-2 vaccine antigen presenting system of an NTD domain protein secreted and expressed by attenuated salmonella typhimurium, and the use thereof, which are used for preventing SARS-CoV-2. By means of constructing a controllable and stable expression plasmid secreting and expressing an NTD domain protein and engineering attenuated salmonella typhimurium, the antigenic protein can be, after administration, efficiently delivered to antigen presenting cells orally and by means of the unique secretion system of the plasmid and the attenuated salmonella typhimurium. The delivered antigenic protein can be efficiently treated and presented by the antigen presenting cells, thereby finally activating/regulating the immune system, producing antibodies, and exerting the effect of a vaccine.

traducir

NOVEL CORONAVIRUS VACCINE BASED ON CONTROLLABLE SECRETORY EXPRESSION OF ATTENUATED SALMONELLA, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF

NºPublicación: WO2022087855A1 05/05/2022

Solicitante:

JIANGSU TARGET BIOMEDICAL RES INSTITUTE CO LTD [CN]

Resumen de: WO2022087855A1

A novel coronavirus vaccine based on controllable secretory expression of attenuated Salmonella, a preparation method therefor, and an application thereof. The method comprises: respectively constructing controllable and stable expression plasmids for secretory expression of different antigen domain proteins of coronavirus and attenuated Salmonella expression strains therefor; and mixing a plurality of attenuated Salmonella antigen presenting strains which are subjected to controllable secretory expression respectively within antigen presenting cells. By way of an oral route, efficient secretory expression can be performed on a plurality of different antigen proteins within the antigen presenting cells by virtue of a specific secretion system after administration. The secretory expressed-antigen proteins can be effectively treated and presented by the antigen presenting cells, ultimately enabling activation/regulation of an immune system, producing an antibody having a higher potency, and functioning as a vaccine.

traducir

ANTIGEN PRESENTING SYSTEM OF NOVEL CORONAVIRUS VACCINE USING ATTENUATED SALMONELLA FOR SECRETING AND EXPRESSING RBD DOMAIN PROTEIN, AND USE THEREOF

NºPublicación: WO2022087856A1 05/05/2022

Solicitante:

NANJING JIRUIKANG BIOTECHNOLOGY RES INSTITUTE CO LTD [CN]
JIANGSU TARGET BIOMEDICAL RES INSTITUTE CO LTD [CN]

CN_114480463_A

Resumen de: WO2022087856A1

An antigen presenting system of a novel coronavirus vaccine using attenuated salmonella for secreting and expressing an RBD domain protein, and the use thereof. The antigen presentation system is used for preventing novel coronavirus (SARS-CoV-2). By means of constructing a controllable and stable expression plasmid that secretes and expresses the RBD domain protein and engineering attenuated salmonella, an antigenic protein can be efficiently delivered to an antigen-presenting cell via an oral route and by means of the specific secretion system thereof after administration. The delivered antigenic protein can be effectively processed and presented by antigen-presenting cells, thereby ultimately realizing the activation/regulation of the immune system, producing antibodies, and exhibiting the function of a vaccine.

traducir

DETECTION OF PATHOGENIC BACTERIA BY CHEMICALLY FUNCTIONALIZED CELLULOSE

NºPublicación: EP3990924A1 04/05/2022

Solicitante:

CENTRE NAT RECH SCIENT [FR]
UNIV NANTES [FR]
UNIV CLERMONT AUVERGNE [FR]

WO_2020260445_A1

Resumen de: EP3757572A1

The present invention concerns the rapid and selective detection of pathogenic bacteria expressing a lectin-type adhesin in a biological environment using a cellulose support functionalized with a ligand of a lectin-type adhesin, and its use for the diagnostic of infection with pathogenic bacteria expressing a lectin-type adhesin, for example in the context of Crohn's disease or in urinary tract infections.

traducir

NOVEL ENTERO-ANTISEPTIC FOR THE TREATMENT OF GASTROINTENSTINAL INFECTIONS IN HUMANS

NºPublicación: EP3991725A1 04/05/2022

Solicitante:

NINKOV DUSAN [HU]

Resumen de: EP3991725A1

The invention relates to a novel compound manufactured with the procedure of synthesis of bouncing Thymol and Carvacrol into one solid and stabile compound. Use of the compound as an active compound/potent entero-antiseptic for the treatment of infectious acute gastroenteritis in humans, caused by E. coli, Salmonella, Campylobacter, Shigella, Vibrio, Yersinia, Listeria, and other bacteria. Additionally, its second formulation, with the coated cellulose, is used as an active compound/potent entero-antiseptic for the treatment of chronic intestinal infections: Crohn's disease (inflammatory bowel disease - IBD).

traducir

BACTERIOCINS FOR CONTROL OF SALMONELLA ENTERICA

NºPublicación: CN114423780A 29/04/2022

Solicitante:

诺麦生物科学有限公司

US_2022073575_A1

Resumen de: EP3378485A1

The present invention relates to bacteriocins for control of Salmonella enterica (salmocins). The bacteriocins are derived from Salmonella. The salmocins can be expressed in plants and can be used in a method of preventing or reducing infection or contamination of an object with Salmonella.

traducir

TREATMENT OF BENIGN NERVOUS SYSTEM TUMORS USING ATTENUATED SALMONELLA TYPHIMURIUM

NºPublicación: US2022125906A1 28/04/2022

Solicitante:

MASSACHUSETTS GEN HOSPITAL [US]

JP_2022522350_A

Resumen de: US2022125906A1

Compositions and methods for the treatment of benign nervous system tumors including schwannomas using attenuated Salmonella typhimurium and optionally one or more checkpoint inhibitors.

traducir

APPARTATUS AND METHODS FOR REAL-TIME CELL MONITORING

NºPublicación: US2022128557A1 28/04/2022

Solicitante:

PHENOFAST LTD [IL]

CN_113874711_PA

Resumen de: US2022128557A1

Systems comprising a diffraction grating, a light source configured to illuminate at a limited waveband, an optical detection system configured to detect zero and non-zero diffraction orders of light, and a signal processing unit adapted to analyze zero and non-zero diffraction orders to determine time-dependent changes in effective optical depth are provided. Methods for use of these systems for real-time detection of cell replication, microorganism detection, and for selecting a therapeutic agent for treating a microorganism are also provided.

traducir

OPTIMIZED CELL-FREE SYNTHESIS OF INVASION PLASMID ANTIGEN B AND RELATED COMPOSITIONS AND METHODS OF USE

NºPublicación: US2022125907A1 28/04/2022

Solicitante:

VAXCYTE INC [US]

EA_202192401_A1

Resumen de: US2022125907A1

The present disclosure provides a cell-free method for synthesizing an Invasion Plasmid Antigen B (IpaB) antigen associated with a Shigella bacterium comprising exogenous addition of the purified chaperone protein IpgC to the cell-free synthesis mixture. The disclosure further provides IpaB antigen mutants comprising non-natural amino acids incorporated during cell-free synthesis, enabling covalent conjugation to a Shigella O-antigen polysaccharide. Further provided are Ipa B antigens and conjugates thereof, as well as immunogenic compositions prepared with the synthesized IpaB antigens and conjugates thereof and methods of use.

traducir

MODIFIED STRAIN OF SALMONELLA ENTERICA TYPHI

Nº publicación: JP2022523135A 21/04/2022

Solicitante:

プロカリウムリミテッド

KR_20210142596_PA

Resumen de: WO2020157203A1

The present invention relates to the modification of a live attenuated strain of Salmonella enterica serovar Typhi, wherein its natural surface-exposed polysaccharide and flagellin antigens may be converted to, or augmented by, those from other strains of Salmonella, including S. enterica serovars Paratyphi, Typhimurium and Enteritidis. The present invention also relates to modified strains of Salmonella enterica serovar Typhi being suitable for use as components of a vaccine for enteric fever and salmonellosis.

traducir

Página1 de 3 nextPage por página

punteroimgVolver